Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations
- 1 September 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 17 (9) , 1842-1853
Abstract
Melanomas are characterized by driver and loss-of-function mutations that promote mitogen-activated protein kinase (MAPK) signaling. MEK inhibitors are approved for use in BRAF-mutated melanoma; however, early-phase clinical trials show occasional responses in driver-negative melanoma, suggesting other alterations conferring MAPK/ERK dependency. To identify additional structural alterations in melanoma, we evaluated RNA-Seq from a set of known MAPK/ERK regulators using a novel population-based algorithm in The Cancer Genome Atlas (TCGA). We identified recurrent MAP3K8 rearrangements in 1.7% of melanomas in TCGA, occurring in more than 15% of tumors without known driver mutations (BRAF, NRAS, KIT, GNAQ, GNA11, and NF1). Using an independent tumor set, we validated a similar rearrangement frequency by FISH. MAP3K8-rearranged melanomas exhibit a low mutational burden and absence of typical UV-mutational patterns. We identified two melanoma cell lines that harbor endogenous truncating MAP3K8 rearrangements that demonstrate exquisite dependency. Rearrangement and amplification of the MAP3K8 locus in melanoma cells result in increased levels of a truncated, active MAP3K8 protein; oncogenic dependency on the aberrant MAP3K8; and a concomitant resistance to BRAF inhibition and sensitivity to MEK or ERK1/2 inhibition. Our findings reveal and biochemically characterize targetable oncogenic MAP3K8 truncating rearrangements in driver mutation–negative melanoma, and provide insight to therapeutic approaches for patients with these tumors. These data provide rationale for using MEK or ERK inhibitors in a subset of driver-negative, MAPK/ERK–dependent melanomas harboring truncating MAP3K8 rearrangements. Implications: This is the first mechanistic study and therapeutic implications of truncating MAP3K8 rearrangements in driver-negative melanoma.Keywords
All Related Versions
Funding Information
- Susan G. Komen for the CureSusan G. Komen for the Cure (Susan G. Komen) (CCR13262005)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (K23CA204726)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (CA098131)
- Susan G. Komen for the CureSusan G. Komen for the Cure (Susan G. Komen) (SAC110030)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (CA183531)
- HHS | NIH | National Institute of General Medical SciencesHHS | NIH | National Institute of General Medical Sciences (NIGMS) (GM008554)
- Howard Hughes Medical InstituteHoward Hughes Medical Institute (HHMI) (MIG56006779)
This publication has 23 references indexed in Scilit:
- Genomic Classification of Cutaneous MelanomaCell, 2015
- Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaJournal of Clinical Investigation, 2015
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- A comprehensive catalogue of somatic mutations from a human cancer genomeNature, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Mutational activation of the MAP3K8 protooncogene in lung cancerGenes, Chromosomes and Cancer, 2004
- The COOH-Terminal Domain of Wild-Type Cot Regulates Its Stability and Kinase Specific ActivityMolecular and Cellular Biology, 2003
- TNF-α Induction by LPS Is Regulated Posttranscriptionally via a Tpl2/ERK-Dependent PathwayCell, 2000
- Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation.Proceedings of the National Academy of Sciences, 1993
- Structure and transforming potential of the human cot oncogene encoding a putative protein kinase.Molecular and Cellular Biology, 1991